INTRODUCTION 25
The gram-negative bacterium Escherichia coli is responsible for 80% of 26 community acquired urinary tract infections (UTI) (38). Uncomplicated UTIs 27 create a significant burden on human health with more than 50% of adult women 28 suffering a UTI during their lifetime (16). An equally large burden is placed on 29 our healthcare system with estimates of direct and indirect costs of $1.6 billion 30 per year in the United States alone (15). While antibiotics have proven to be an 31 effective treatment in the past, a worldwide increase in antibiotic resistance in 32 uropathogenic E. coli (UPEC) isolates (1, 6, 8, 14) has created an urgent need 33 for alternative treatment and prevention strategies to combat this important and 34
widespread human pathogen. 35
In addition to the core genetic backbone of this species, UPEC contain a 36 unique repertoire of genetic material distinct from what is present in commensal 37 strains or other E. coli pathotypes (39). This set of accessory genes provides the 38 mechanisms for colonizing the host urinary tract and eliciting the signs and 39 symptoms of an uncomplicated UTI (28). The host urinary tract environment 40 challenges bacteria with an immune response that the bacteria must overcome 41 to persist in the host (33). Recently, our group correlated antibody production 42 with protection in a mucosal vaccination model using several vaccine candidates 43 that targeted iron acquisition system proteins expressed in vivo by human UPEC 44 strains (2). This suggested that eliciting a humoral immune response to UPEC 45 surface proteins, some encoded by specific accessory genetic sequences, may 46 be beneficial in creating novel UPEC vaccines. Clearly, new candidate vaccine 47
After DNase inactivation, RNA was recovered, quantified, and used as a 152 template for PCR to confirm inactivation of contaminating DNA. The PCR-153 negative RNA was used for first strand cDNA synthesis using SuperScript II 154 reverse transcriptase (Invitrogen). For cDNA synthesis, the manufacturer's 155 protocol was followed, starting with 1.35 µg total RNA template and 50 ng 156 random hexamers. Following synthesis, the cDNA was purified on a QIAquick 157 column (Qiagen), quantified using the NanoDrop, and diluted to 5 ng/µl with 158 nuclease-free water. RNA transcripts were quantified on an MX3000P real-time 159 PCR machine (Stratagene) using Brilliant SYBR green QPCR mix (Stratagene) in 160 25 µl volumes containing 25 ng cDNA. Optimal primer concentrations were 161 determined empirically. For comparative, quantitative analysis, transcript levels 162 were normalized to the level of gapA (glyceraldehyde 3-phosphate 163 dehydrogenase A) and changes were determined using an experiment-specific 164 calibrator (LB) using MXPro v 3.00 software package (Stratagene). For in vivo 165 quantitative PCR, RNA was purified as described from pooled urine from groups 166 of mice experimentally infected with CFT073 to determine transcript levels during 167
UTI. 168
Construction of mutants in UPEC strain CFT073. Deletion mutants were 169 generated using the lambda red recombinase system (12). Primers homologous 170 to sequences within the 5' and 3' ends of the target genes were designed and 171 used to replace target genes with a nonpolar kanamycin resistance cassette 172 derived from the template plasmid pKD4 (12). Kanamycin (25 µg/ml) was used 173 immobilized on a membrane in order to expose the serum to both surface-217 exposed and non-exposed proteins synthesized during in vitro growth. This 218 adsorption process was repeated with host expression strain E. coli BL21 (DE3) 219 pLysS that carried the genomic expression library used for the IVIAT screening. 220
Multiple rounds of adsorption were conducted until colony immunoblots of both 221 bacterial strains registered negligible background levels of reactivity with the 222 treated serum when compared to unabsorbed serum (Fig. 1A-C) . 
genome. 235
Primary screening of the adsorbed serum was conducted using colony 236 immunoblots of the genomic expression library. 461 clones that exhibited 237 reactivity significantly above background ( Fig. 1D and E) were isolated and 238 subjected to a second round of screening. Three replicate colony immunoblots 239
were conducted during secondary screening to minimize false positives. A total 240 of 83 clones remained reactive to the adsorbed serum in at least two of the three 241 replicate screens. Plasmids from these clones were isolated and sequenced to 242 identify the gene fragments identified by the IVIAT screening (Table 1) . Ten 243 inserts contained DNA that spanned two genes, bringing the total number of 244 candidate in vivo-expressed genes to 93. 245
A subset of the IVIAT-identified genes have known roles during UPEC 246 colonization of the urinary tract and were not further investigated in this study. 247 iucC and fhuC, both involved in hydroxymate sideophore transport, were 248 identified in our screen, which is consistent with iron acquisition being a key 249 virulence trait for UPEC during UTI. NanA, involved in the transport and 250 catabolism of sialic acid was previously shown to be up-regulated in human 251 urine, however a mutant had no apparent fitness defect during UTI (4). (Fig. 2) . CFT073 305 mutants in each of these genes were competed against wild-type CFT073 in co-306 challenge infections or tested in independent challenge in the murine model of 307 ascending UTI. CFU levels in bladder and kidney were quantified for each strain 308 at 48 hours post inoculation ( Fig. 3 and 4) . 309
In a previous study, our group reported on the contribution of the 100-kb 310 pathogenicity associated island PAI CFT073 -aspV containing the RTX family 311 member tosA to fitness in the murine urinary tract (26). In the current study, 312
IVIAT independently identified TosA as an antigen that is preferentially 313 expressed in vivo (Table 2 and Fig. 2A) . tosA expression was determined to be 314 specific to the in vivo environment and expression above background levels was 315 not observed when bacteria were cultured in vitro in pooled filter-sterilized human 316 urine (Fig. 2B) . A ∆tosA mutant of CFT073 was tested in the murine model of 317 ascending UTI and colonization levels in the bladder and kidneys were compared 318 to colonization levels observed when the parental wild type strain was 319 independently tested (Fig. 3) . The ∆tosA mutant was severely attenuated in the 320 animal model of infection; significantly lower numbers of bacteria were recovered 321 from both bladder (P=0.0016) and kidney (P=0.0120) tissue compared to the 322 wild-type strain. Thus, the IVIAT approach employed in this study identified a The proWX genes are involved in osmoregulation by encoding the proline 328 betaine transport system. An isogenic mutant that contained a single deletion 329 covering the proW and proX genes, corresponding to the region of the genome 330 contained in a single expression clone identified by IVIAT, was outcompeted by 331 the parental strain in the kidney (P=0.0024) (Fig. 4A) . The data from this co-332 challenge illustrate that the IVIAT screen may identify genes and systems that 333 confer an advantage during UPEC colonization of the urinary tract. 334
The mutant lacking catalase encoded by katG was recovered in numbers 335 equal to wild-type (Fig. 4B ) and thus did not confer a fitness advantage and could 336 not be considered a virulence factor. Surprisingly, the ∆adhP mutant lacking an 337 alcohol peroxidase (Fig. 4C) , which was very highly expressed in human urine 338 (Fig. 2B) , and the ∆narJI mutant lacking an anaerobic nitrate reductase I (Fig.  339   4D) were both recovered in significantly higher numbers than wild-type in the 340 bladder (P=0.0391) and kidneys (P=0.0156), respectively. While each of these 341 genes was properly identified by the IVIAT approach as being expressed at 342 higher levels in vivo ( Fig. 2A) Two of the genes identified by the IVIAT screening approach employed in 350 this study, a putative secreted RTX family exoprotein (tosA) and an 351 osmoprotection system that transports glycine betaine (proWX), contribute to 352 fitness of UPEC in the host urinary tract (Fig. 3 and 4) . In addition, more than 90 353 additional genes were identified by IVIAT (Table 1 ) and many of these may also 354 contribute to pathogenesis of UTI. Of particular note is the observation that out 355 of the 93 identified genes, 23 genes have not been previously studied and were 356 assigned a function based only on sequence homology to known proteins. 357
Seventeen additional genes did not demonstrate sufficient homology to be 358 assigned function. The putative RTX family member tosA (originally annotated as 359 upxA (39)), which was determined in this study to contribute significantly to the 360 ability of the human pyelonephritis isolate CFT073 to colonize a murine UTI 361 model (Fig. 3) , is just one example from this group of genes of unknown function. 362
Because the IVIAT method relies on antibodies made by the host during an 363 infection (30), this list also represents UPEC antigens that the host immune 364 system recognized and against which an immune response was mounted. While 365 additional studies will be needed to clarify the role of those genes not pursued 366 further in this study, this list may contain useful targets for the development of a 367
UPEC vaccine. 368
Several limitations of the project must be addressed to clarify the results of 369 this study. Due to the limited quantity of murine antiserum available, only 40,000 370 clones of the genomic expression library were screened. Because our group 371 on September 23, 2017 by guest http://iai.asm.org/ Downloaded from calculated that ~50,000 clones would be needed to obtain 95% genome 372 coverage, Table 2 represents only a partial but nevertheless substantial list of 373 genes preferentially expressed in vivo and their proteins that are recognized as 374 antigenic by the host. In addition, for a gene product to be recognized by IVIAT, 375 the antibody titer must be sufficiently high to obtain a consistently strong signal 376 on immunoblot in both primary and secondary screening. Next, any proteins 377 produced during in vitro growth, even those with known contributions to fitness in 378 the urinary tract, would be available to remove specific antibodies during the 379 serum adsorption process and are not predicted to be recognized by IVIAT. 380
Finally, there was difficulty constructing a stable plasmid containing the 4.8 kb 381
tosA gene, and thus complementation was not confirmed in the independent 382 challenge ( Figure 3 ). These limitations may explain why many well characterized 383 UPEC virulence factors, such as P fimbriae, which are known to be expressed 384 during in vitro growth on LB agar (10), were not identified by this screen. 385
Despite these caveats, the results of the IVIAT screen clarify and reinforce 386 previous observations about general metabolic processes that UPEC employ to 387 colonize the host urinary tract. Our findings also revealed some overlap with a 388 similar screen in enterohemorrhagic E. coli (EHEC) carried out using 389 convalescent sera from patients following recovery from hemolytic uremic 390 the genes adhP, katG, and narJ and narI, were all successful in competing 404 against wild type CFT073 during co-challenge experiments (Fig. 4) . Each of 405 these genes were determined to be upregulated in vivo compared to growth in 406 LB medium, and expression of the genes narJ, narI, and katG were specific to 407 the in vivo environment and were not induced during growth in pooled filtered 408 
Downloaded from
The genes proW and proX, part of the proU osmoprotection system, 417 increase fitness of the human pyelonephritis isolate CFT073 in the kidneys of 418 infected mice (Fig. 4) . A trend toward lower CFU of the ∆proWX mutant was also 419 observed in the bladder on co-challenge with wild-type CFT073. Previous 420 research had identified the major substrates of the proU system in E. coli as 421 glycine betaine and proline betaine (17). Both compounds are present in human 422 urine and the presence of either compound increases the tolerance of E. coli to 423 higher concentrations of osmotic agents than observed without the compounds 424 present (9), suggesting an important role for the transport of these compounds as 425 an adaptation by UPEC to survive the environment of the host urinary tract. 426
Additional studies on the role of the proU system in the human pyelonephritis 427 strains CFT073 and HU734 found ∆proU mutants of each strain colonized the 428 murine model of an ascending UTI at the same levels as wild type in both 429 bladder and kidneys of infected mice (11). Additional osmoprotection systems 430 have been identified in E. coli (11, 42) and this functional redundancy may help 431 explain why a strain of UPEC that lacks the proU system can still efficiently 432 colonize the urinary tract. In contrast to the current study that mixed wild type 433 CFT073 at an equal ratio to mutant and co-inoculated the two strains in the same 434 animal, previous experiments were conducted as independent challenges of 435 each strain's ability to colonize infected mice in separate infections. Indeed, we 436 consider co-challenge a more sensitive index of fitness than independent 437 challenge. When considered together, the results of this study help to clarify the 438 role of the proU osmoprotection system during an experimental UTI. While this 439 system is not necessary for colonization, the expression of the system is strongly 440 induced in both an in vivo infection model and growth in vitro in human urine, and 441 the presence of the system contributes enhanced fitness of UPEC in the kidneys 442 of infected animals. 443
The IVIAT-identified gene tosA (upxA) was originally described in the (Fig. 2B) . This limited expression pattern stands in contrast to hlyA, the gene that 463 encodes the prototype RTX toxin α-hemolysin, which is expressed during in vitro 464 growth in LB medium (25), the same conditions utilized for the RT-qPCR study 465 presented in Figure 2B . While the UPEC strain CFT073 contains the two RTX 466 family members tosA and hlyA, the regulatory mechanisms governing expression 467 of each system appear to be different. This raises the possibility that a specific 468 host factor, not present in human urine, may trigger the expression of tosA 469 observed in this study. 470
A ∆tosA strain of CFT073 was attenuated in both the bladder and kidneys 471 of infected mice following independent challenge (Fig. 3) . While our previous 
